RxDoctor Payments Data

Larry Wood, MD

Ophthalmology · Waco, TXNPI 1659406072

Payments from drug & device makers

$3,342in general payments, 2019–2025

Across 69 payments — averaging $48.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • UCB, Inc.$171
  • Amgen$150
  • Upsher-smith Laboratories LLC$150
  • Neurocrine Biosciences, Inc.$122
  • Argenx US, Inc.$104
  • plus $478 from 11 others

What the payments were for

  • Speaking & faculty fees$341%
  • Travel & lodging$1,83555%
  • Food & beverage$1,47344%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,342 in reported general payments places this provider in the 60th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$234,429
Medicare patients
805
Services billed
1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost28$14,774
Prednisolone Acetate283$12,330
RocklatanNetarsudil Mesylat/Latanoprost14$5,862
Latanoprost469$5,527
SimbrinzaBrinzolamide/Brimonidine Tart20$5,309
MoxifloxacinMoxifloxacin Hcl222$4,940
RhopressaNetarsudil Mesylate13$3,864
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat218$3,499
Ketorolac Tromethamine177$2,868
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$2,258
Timolol MaleateTimolol Maleate/Pf13$2,070
Timolol Maleate71$577
Brimonidine Tartrate65$507
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$335
Dorzolamide Hcl12$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$20$14,77428 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$25$9,72627 claims
AlconSimbrinza$90$5,30920 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$47$21819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →